Page 17 - Biomarkers for risk stratification and guidance in heart failure
P. 17
Chapter 1
REFERENCES
1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European heart journal 2012;33:1787-847.
2. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007;93:1137-46.
3. Hartfalen, Cijfers & Context, Trends en toekomst. 2015. (Accessed 18-06-2015, 2015, at https://www. volksgezondheidenzorg.info/onderwerp/hartfalen/cijfers-context/trends-en-toekomst - node-trends- de-toekomst-0.)
4. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. The New England journal of medicine 1987;316:1429-35.
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England journal of medicine 1999;341:709-17.
7. Maggioni AP, Anand I, Gottlieb SO, et al. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology 2002;40:1414-21.
8. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-85.
9. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. The New England journal of medicine 2014;371:993-1004.
10. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. The New England journal of medicine 2005;352:1539-49.
11. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. The New England journal of medicine 2005;352:225-37.
12. Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Archives of internal medicine 2008;168:2481-8.
13. Hartfalen, Kosten. 2015. (Accessed 18-06-2015, at https://www.volksgezondheidenzorg.info/ onderwerp/hartfalen/kosten/kosten - node-kosten-van-zorg-voor-hartfalen.)
14. Davie AP, Francis CM, Caruana L, Sutherland GR, McMurray JJ. Assessing diagnosis in heart failure: which features are any use? QJM : monthly journal of the Association of Physicians 1997;90:335-9.
15. Manning HL, Schwartzstein RM. Pathophysiology of dyspnea. The New England journal of medicine 1995;333:1547-53.
16. Ray P, Birolleau S, Lefort Y, et al. Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis. Critical care 2006;10:R82.
17. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. Journal of the American College of Cardiology 2003;42:728-35.
18. Bayes-Genis A, Santalo-Bel M, Zapico-Muniz E, et al. N-terminal probrain natriuretic peptide (NT- proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. European journal of heart failure 2004;6:301-8.
19. Michelson E, Hollrah S. Evaluation of the patient with shortness of breath: an evidence based approach. Emergency medicine clinics of North America 1999;17:221-37, x.
20. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. Jama 2004;291:2727-33.
21. Nendaz MR, Bandelier P, Aujesky D, et al. Validation of a risk score identifying patients with acute pulmonary embolism, who are at low risk of clinical adverse outcome. Thrombosis and haemostasis 2004;91:1232-6.
16
